ArticleBlood cancer journal2018
CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Integrative pan-cancer analysis of dipeptidyl peptidase 4 with clinical andFrontiers in immunology · 2026Article
- Novel immunotargets in multiple myeloma: biological relevance and therapeutic potential.Biomarker research · 2025Review
- HDAC Inhibition Induces CD26 Expression on Multiple Myeloma Cells via the c-Myc/Sp1-mediated Promoter Activation.Cancer research communications · 2024Article
- Multiomics surface receptor profiling of the NCI-60 tumor cell panel uncovers novel theranostics for cancer immunotherapy.Cancer cell international · 2022Article
- Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases.Molecules (Basel, Switzerland) · 2022Review
- CD26/DPP-4 in Chronic Myeloid Leukemia.Cancers · 2022Review
- Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?Cancers · 2022Review
- Distinctive CD26 Expression on CD4 T-Cell Subsets.Biomolecules · 2021Article
- Review
- Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review.Cancers · 2021Review
- Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.Biomarker research · 2021Article
- Leukocyte Membrane Enzymes Play the Cell Adhesion Game.Frontiers in immunology · 2021Review
- An expanded role for dipeptidyl peptidase 4 in cell regulation.Current opinion in hematology · 2020Review
- Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.Pharmacology & therapeutics · 2020Review
- Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer.Scientific reports · 2020Article
- DPP8 is a novel therapeutic target for multiple myeloma.Scientific reports · 2019Article
- Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.Journal of oncology · 2019Review
- Lightwave-reinforced stem cells with enhanced wound healing efficacy.Journal of tissue engineeringArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD26, a 110-kDa transmembrane glycoprotein that is expressed on several tumor cells including malignant lymphoma, has been implicated in tumorigenesis: however, little is known regarding its role in multiple myeloma (MM). Recently, we identified CD26 expression on human osteoclasts (OCs) and demonstrated that humanized IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.